Skip to main content
Premium Trial:

Request an Annual Quote

MDS' Q4 Revenues Fall 4 Percent

NEW YORK (GenomeWeb News) – MDS today reported that its fourth-quarter revenues fell 4 percent, as its Analytical Technologies and Pharma Services units both had declines in revenues year over year.
The Toronto-based firm brought in revenues of $322 million for the three-month period ended Oct. 31, compared with revenues of $327 million for the fourth quarter of 2007. MDS said that excluding the impact of foreign exchange and acquisitions and divestitures, the firm’s revenues were up 4 percent.
MDS Analytical Technologies, which houses the firm’s mass spectrometry and Molecular Devices businesses, had a drop in revenue to $99 million from $108 million. The firm said that the division continues to be impacted by soft demand for high-end instruments.
MDS Pharma Services’ Q4 revenues fell to $112 million from $123 million year over year, and revenues for MDS Nordion grew to $84 million from $76 million.
The company posted a net loss of $255 million, or $2.11 per share, due primarily to a $501 million write-off during the quarter associated with its investment in the MAPLE nuclear-reactor project. MDS posted a profit of $15 million, or $.13 per share, for the comparable period of 2008. The fourth-quarter results also include a $160 million benefit for forgiveness of debt related to the MAPLE project, which was scrapped earlier this year. MDS has since filed a $1.6 billion court claim related to the project.
MDS’ SG&A costs for the quarter declined 8 percent year over year to $77 million from $84 million, while its R&D spending dropped 30 percent to $14 million from $20 million.
For full-year 2008, MDS brought in revenues of $1.3 billion, up 8 percent from revenues of $1.2 billion in 2007. The results are better than the revenue range of between $1.21 billion and $1.22 billion the firm predicted last week.
The firm’s net loss for the year was $233 million, or $1.91 per share, versus a profit of $781 million, or $5.92 per share, in 2007. Last year’s results include an $806 million gain from the sale of the firm’s Canadian diagnostics business.
MDS finished fiscal 2008 with $120 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.